After reading these articles, you should be able to…

While drug companies have been working hard to come up with new options for the treatment of dementia, there have been no new FDA approvals since memantine (Namenda) hit the scene in 2003.

Let’s assume that you have already diagnosed a patient with Alzheimer’s Disease (AD). Your patient has received a full workup to rule out medical causes, has had a full battery of neuropsychological tests, and you have started a standard cocktail of whichever cholinesterase inhibitor you prefer.

As a neurologist, how do you approach the evaluation of dementia symptoms?

Omega 3 fatty acids were once thought to be a possible treatment for mood disorders—but recent studies have been unimpressive.

The frequency of antidepressant induced mania has been elusive, with some studies finding high rates of manic switching and others finding very few or no manic episodes among patients taking antidepressants.

Previous research has shown that a single dose of d-amphetamine 30 mg (as monotherapy) relieves symptoms of OCD better than a placebo ...

After reading these articles, you should be able to…

Trying to fit everything you need to know about professional ethics in one article is a nearly impossible task. But somebody’s got to do it—or at least attempt it!

The ethical practices of the pharmaceutical industry have recently come under scrutiny as never before. Here is a quick rundown of the main issues involved and what reforms have taken place, or may soon take place.